Cases & Deals

Neurocrine Biosciences expands patent portfolio related to use of INGREZZA (valbenazine) in treatment of abnormal movement disorders

Clients Neurocrine Biosciences, Inc.

Jones Day represents Neurocrine Biosciences, Inc. in prosecution of patent portfolio directed to use of INGREZZA (valbenazine) in treatment of abnormal movement disorders, including tardive dyskenisia and Tourette’s syndrome.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.